Heparin-coated cardiopulmonary bypass circuits: current status

Area of Science:

• Biomaterials Science
• Cardiovascular Surgery
• Immunology

Background:

• Heparin-coated circuits have undergone extensive experimental and clinical evaluation over the past decade.
• Preserved heparin function on surfaces attenuates systemic inflammatory responses.
• These surfaces also offer protein resistance and enhanced lipoprotein binding, contributing to biocompatibility.

Purpose of the Study:

• To evaluate the multifaceted roles of heparinized surfaces in mitigating inflammatory responses during cardiopulmonary bypass (CPB).
• To assess the clinical effectiveness of heparin-coated circuits when integrated into a global biocompatibility strategy.
• To compare outcomes with conventional CPB techniques and alternative revascularization procedures.

Main Methods:

• Experimental and clinical testing of heparin-coated circuits.
• Assessment of heparin surface function in attenuating contact activation, coagulation, complement, platelet, and leukocyte activation.
• Implementation and evaluation of a global biocompatibility strategy to minimize material-independent blood activation.

Main Results:

• Heparinized surfaces effectively attenuate multiple components of the inflammatory cascade.
• These surfaces enhance CPB circuit biocompatibility by rendering them hydrophilic and protein-resistant.
• Clinical integration with a global biocompatibility strategy significantly improves patient outcomes, including morbidity and mortality.

Conclusions:

• Heparin-coated circuits, when used with a comprehensive biocompatibility strategy, offer substantial clinical benefits.
• This approach optimizes patient outcomes and graft patency in cardiovascular procedures.
• Future revascularization strategies should aim to match or exceed the efficacy of conventional CPB with proven biocompatibility measures.